Analyst
Chief of Discovery and Translational Medicine
Equibles does not estimate personal net worth.
James Hamilton is recorded as Analyst at Chief of Discovery and Translational Medicine. The proxy statement of Arrowhead Pharmaceuticals, Inc. reports total compensation of $3,487,444 for James Hamilton in fiscal 2024, including a base salary of $567,937. Disclosed compensation is on record for 5 fiscal years. James Hamilton has spoken on 5 earnings calls and 3 other investor events across 1 company, most recently for Arrowhead Pharmaceuticals, Inc. on September 15, 2026. Arrowhead Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arrowhead Pharmaceuticals, Inc. includes Christopher Anzalone (CEO and Board Member), Daniel Apel (CFO), Patrick O'Brien (COO) and 7 others.
“Yeah, I think one of the things to emphasize in the data we released this morning was the APLB reduction, fairly large APO-B reduction of about 50%.”
“Just for folks new to the story, high level, I think most people know we're an sRNA therapeutics We don't do anything else, just sRNA drugs, no gene therapy or gene editing, at least not yet.”
“Yeah, so I think, as we've said before, we remain cautiously optimistic about our ability to be stat sig on AP. and based on the blinded event rate, again, we remain confident that we'll be sufficiently powered in terms of number of events.”
“I'd like to start with a review of the Redemplo FDA approval and information in the label and contained in the package insert. Redemplo is approved as an adjunct to diet to reduce triglycerides in adults with FCS.”
“With our sharpened focus on the cardiometabolic therapeutic area, I'd like to discuss our two new programs for obesity and metabolic disease. Clearly, there have been advancements in the obesity space of late.”
Chief of Discovery and Translational Medicine
Analyst
Source not stated
Proxy statement
Start not stated–present
Last confirmed January 27, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Arrowhead Pharmaceuticals, Inc. (ARWR) | Chief of Discovery and Translational Medicine | $567,937 | $3,487,444 |
| 2023 | Arrowhead Pharmaceuticals, Inc. (ARWR) | Chief of Discovery and Translational Medicine | $511,178 | $3,046,943 |
| 2022 | Arrowhead Pharmaceuticals, Inc. (ARWR) | Chief of Discovery and Translational Medicine | $450,436 | $4,323,314 |
| 2021 | Arrowhead Pharmaceuticals, Inc. (ARWR) | Chief of Discovery and Translational Medicine | $426,109 | $4,509,947 |
| 2020 | Arrowhead Pharmaceuticals, Inc. (ARWR) | Chief of Discovery and Translational Medicine | $376,362 | $3,412,877 |
